Pertuzumab for the treatment of ovarian cancer

Bibliography

• Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;10:167-81
   Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Cancer Statistics 2008. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8
   PubMed Web of Science ®Google Scholar
• Markman M, Webster K, Zanotti K, Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 2003;90:593-606
   PubMed Web of Science ®Google Scholar
• D'Agostino G, Amant F, Berteloot P, Phase II study of gemcitabine in recurrent platinumand paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003;88:266-9
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kaye S. Ovarian cancer: strategies to overcome resistance to chemotherapy. Nat Rev Cancer 2003;3:502-16
   PubMed Web of Science ®Google Scholar
• Palayejkar MJ, Herzog TJ. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int J Gynecol Cancer 2008;18:879-90
   PubMed Web of Science ®Google Scholar
• Badache A, Hynes NE. A new therapeutic antibody masks erbB2 to its partners. Cancer Cell 2004;5:299-301
   PubMed Web of Science ®Google Scholar
• Langdon SP, Mullen P, Faratian D, Pertuzumab. Drugs Future 2008;33:1-8
   Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ErbB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54
   PubMed Web of Science ®Google Scholar
• Moasser MM. The oncogene HER2: its signalling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26:6469-87
   PubMed Web of Science ®Google Scholar
• Graus-Porta D, Beerli RR, Daly JM, ErbB-2, the preferred heterodimerization partner of all ErbB receptors is a mediator of lateral signalling. EMBO J 1997;16:1647-55
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12
   PubMed Web of Science ®Google Scholar
• Berchuck A, Kamel A, Whitaker R, Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91
   PubMed Web of Science ®Google Scholar
• Meden H, Marx D, Rath W. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 1994;13:45-53
   PubMed Web of Science ®Google Scholar
• Agus DB, Akita RW, Fox WD, Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-37
   PubMed Web of Science ®Google Scholar
• Friess T, Scheuer W, Hasmann M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005;11:5300-9
   PubMed Web of Science ®Google Scholar
• Jackson JG, St Clair P, Sliwkowski MX, Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 2004;64:2601-9
   PubMed Web of Science ®Google Scholar
• Mullen P, Cameron DA, Hasmann M, Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalling. Mol Cancer Ther 2007;6:93-100
   PubMed Web of Science ®Google Scholar
• Takai N, Jain A, Kawamata N, 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 2005;104:2701-8
   PubMed Web of Science ®Google Scholar
• Makhija S, Amler LC, Glenn D, Clinical Activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2010;28:1215-23
   PubMed Web of Science ®Google Scholar
• Nagumo Y, Faratian D, Mullen P, Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity. Mol Cancer Res 2009;7:1563-71
   PubMed Web of Science ®Google Scholar
• Agus DB, Gordon MS, Taylor C, Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-43
   PubMed Web of Science ®Google Scholar
• Gordon MS, Matei D, Aghajanian C, Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24:4324-32
   PubMed Web of Science ®Google Scholar
• Kaye SB, Poole CJ, Bidzinksi M, A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin based therapy alone in patients with relapsed,platinum sensitive ovarian cancer [abstract 5520]. J Clin Oncol 2008;26(Suppl):305s
   Google Scholar
• ASCO Media Player. Available at: http://media.asco.org/silver/AstuteMediaPlayer.aspx?ConferenceID= 55&TrackID=5&SessionID=392& PresentationID=11974&Token [Last accessed 28 April 2010]
   Google Scholar
• Hudis CA. Mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51
   PubMed Web of Science ®Google Scholar
• Bookman MA, Darcy KM, Clarke-Pearson D, Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283-90
   PubMed Web of Science ®Google Scholar
• Burris HA, Hurwitz HI, Dees EC, Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-13
   PubMed Web of Science ®Google Scholar
• Rivkin SE, Muller D, Iriarte D, Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients. J Clin Oncol 2008;26:5556
   Google Scholar
• Kimball KJ, Numnum TM, Kirby TO, A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol 2008;111:95-101
   PubMed Web of Science ®Google Scholar
• Campos S, Hamid O, Seiden MV, Multicenter randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol 2005;23:5597-604
   PubMed Web of Science ®Google Scholar
• Balsega J, Gelmon KA, Verma S, Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-44
   PubMed Web of Science ®Google Scholar
• Scheuer W, Friess T, Burtscher H, Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69:9330-6
   PubMed Web of Science ®Google Scholar